{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06800313","nct_id":"NCT06800313","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06800313. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"JNJ-101556143 Phase 1 Part 1 - Dose Escalation","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"JNJ-101556143 Phase 1 Part 2 - Formulation Exploration","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"JNJ-101556143 Phase 2 Part 1 - Dose Optimization","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"Phase 2 Part 2A - SOAR","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"Phase 2 Part 2B - HSPC Expansion","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"Phase 2 Part 2C - HSPC Expansion","type":"EXPERIMENTAL"},{"description":"Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)","label":"Phase 2 Part 2D - HSPC Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-08-17","type":"ESTIMATED"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":190,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"JNJ-101556143 Formulation 1","otherNames":[],"type":"DRUG"},{"name":"JNJ-101556143 Formulation 2","otherNames":[],"type":"DRUG"},{"name":"JNJ-101556143 Formulation 3","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-08-17","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Frequency of dose-limiting toxicities (DLTs)","timeFrame":"21 days"},{"measure":"Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline","timeFrame":"21 days"},{"measure":"Phase 1 Part 2 (formulation exploration) relative bioavailability","timeFrame":"22 days"}],"references":[],"start_date":{"date":"2025-02-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06800313"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06800313"}